Supriya Sharma

To provide funding for the Canadian Collaboration to Cure ALS, to establish a coordinated national research ecosystem through which every Canadian living with ALS can participate in, and benefit from, cutting-edge science that will accelerate discoveries by Canadian researchers, advance understanding of the disease, and enable the development of therapies to treat this devastating terminal illness with greater precision. Sources of funding are to be determined. Policies or programs related to access to care and potential treatments for the ALS Community. Amendment to the compassionate care program to make it more accessible to caregivers and to increase the length of the benefit.

Communications regarding medical assistance in dying with respect to advance requests, the state of palliative care, and the protection of Canadians with disabilities. Law enforcement also includes Search and Rescue and “dementia friendly communities”. Canadian Institutes of Health Research (CIHR) - as it relates to increased federal funding and long-term investment in dementia research exceeding 1% of direct dementia care costs (aspirational goal in national dementia strategy). Support for health research infrastructure and continued CIHR partnerships with charitable non-profits like ASC. Budget 2025 - Canada Strong as as it relates to dementia and caregiving as national challenges that require coordinated action across governments and communities. Support for health data, AI, and innovation investments. Continued support for the National Dementia Strategy with targeted investments to reduce impact and costs associated with dementia care. Communications regarding the Canada Disability Benefit to ensure accessibility for individuals with cognitive impairment, including with Alzheimer's or other dementias. Create and fund programs to support Canadians diagnosed with young-onset dementia. Communications regarding the Canada Post strike and its adverse financial impacts (i.e. donations) on the charitable sector. Communications regarding potential funding to Alzheimer Society Research Program for research to study the topic of Veterans and Dementia in a truly Canadian context. Communications regarding the need for $20 million over 5 years through programs like Age Well at Home, and a longer-term and larger commitment to programs like ASC's FirstLink® that have been proven to support people with dementia to live well as long as possible at home and in the community. Communications regarding the need to invest $15 million over 3 years to implement national standards for diagnosis, treatment and care for Alzheimer’s disease and dementia. This will ensure that the health systems across the country have access to quality standards to be able to realize the benefits of any disease modifying drugs approved in Canada. Health Canada as it pertains to the approval of disease-modifying treatments for Alzheimer's disease and other dementias that aim to slow or halt the progression of the disease. National standards and Safe Long-term Care Act include a common standard for the definition of an Essential Care Partner (ECP). Improve access to palliative and end-of-life care for people living with dementia in Canada. Implementation metrics and success criteria for "A Dementia Strategy for Canada:Together We Aspire." Funding opportunities under PHAC's Dementia Community Investment and Dementia Strategic Fund to support awareness-raising, dementia guidelines, diversity & Inclusion and best practices.

Communications regarding the Canada Disability Benefit to ensure accessibility for individuals with cognitive impairment, including with Alzheimer's or other dementias. Create and fund programs to support Canadians diagnosed with young-onset dementia. Communications regarding medical assistance in dying with respect to advance requests, the state of palliative care, and the protection of Canadians with disabilities. Budget 2025 - as it relates to full and sustainable funding by the Government of Canada in: A Dementia Strategy for Canada: Together We Aspire Canadian Institutes of Health Research (CIHR) - as it relates to increased federal funding and long-term investment in dementia research exceeding 1% of direct dementia care costs (aspirational goal in national dementia strategy) Communications regarding the Canada Post strike and its adverse financial impacts (i.e. donations) on the charitable sector. Communications regarding potential funding to Alzheimer Society Research Program for research to study the topic of Veterans and Dementia in a truly Canadian context. Communications regarding the need for $20 million over 5 years through programs like Age Well at Home, and a longer-term and larger commitment to programs like ASC's FirstLink® that have been proven to support people with dementia to live well as long as possible at home and in the community. Communications regarding the need to invest $15 million over 3 years to implement national standards for diagnosis, treatment and care for Alzheimer’s disease and dementia. This will ensure that the health systems across the country have access to quality standards to be able to realize the benefits of any disease modifying drugs approved in Canada. Health Canada as it pertains to the approval of disease-modifying treatments for Alzheimer's disease and other dementias that aim to slow or halt the progression of the disease. National standards and Safe Long-term Care Act include a common standard for the definition of an Essential Care Partner (ECP). Improve access to palliative and end-of-life care for people living with dementia in Canada. Implementation metrics and success criteria for "A Dementia Strategy for Canada:Together We Aspire." Funding opportunities under PHAC's Dementia Community Investment and Dementia Strategic Fund to support awareness-raising, dementia guidelines, diversity & Inclusion and best practices.

International trade regarding tobacco control, alcohol, products containing carcinogens and products associated with cancer. Internal trade regarding tobacco control, alcohol, products containing carcinogens and products associated with cancer. Funding for programs to be operated by the Canadian Cancer Society to advance cancer control. Canadian Partnership Against Cancer, as it relates to continued federal funding for the cancer control strategy Canada Health Transfer and health system bilateral funding agreements intended for provinces/territories to support the delivery of healthcare services Framework Convention on Tobacco Control, including protocols, guidelines and implementation Tobacco and Vaping Products Act, as it relates to regulations, implementation and enforcement Non-Smokers' Health Act including implementation and enforcement Food and Drugs Act and regulations, as it relates to nciotine replacement products Federal Tobacco Control Strategy, including all matters related to tobacco control Taxation, revenue measures, controlled products regulations, including implementation, for alcohol, tobacco control, products containing carcinogens and products associated with cancer. Communication regarding alcohol consumption guidance. Food and Drugs Act and regulations, as it relates to alcohol warning labels Food and Drugs Act and regulations, as it relates to restricting the advertising to children of foods high in sodium, sugars and saturated fat. Healthy Living - Supporting initiatives, legislation, regulation, policies, and programs that prevent cancer or improve the social determinants of health Adoption of HPV testing and increasing HPV vaccination rates Sustainable funding of the National Advisory Committee on Preventive Health Services to ensure timely, up?to?date cancer screening guidelines Equitable and timely access to cancer screening. Measures and funding related to the charitable sector generally Equitable access to care along the full cancer continuum for First Nations, Inuit and Métis communities Employment Insurance special benefit programs, including the sickness benefit and compassionate care benefit Canada Labour Code and Employment Insurance Act, as it relates to job-protected leave, employment insurance special benefits, return to work policies, and human rights protections for people affected by cancer Access to information and support to make decisions regarding end-of-life care, including Medical Assistance In Dying Supports for mental health during people's cancer journeys Implementation and funding of the National Grief Action Plan as part of the government's work on palliative care and mental health Canada Health Act as it relates to access to care, including long-term, home, and palliative care National Caregiving Strategy Financial supports for caregivers, including the Canada Caregiver Credit Implementation of the Framework on Palliative Care in Canada and integration of a palliative approach to care in our health system, including national standards and data, care provider training, research, and implementation of the National Grief Action Plan and distinctions?based frameworks for First Nations, Inuit and Métis people Setting and measuring pan-Canadian wait time benchmarks and targets and measures to address them, including addressing healthcare shortages, increased and sustainable funding for care, infrastructure and equipment, targeted strategic funding to PTs for workforce shortages, particularly in rural and remote communities. Sustained core funding for federal research agencies, improved coverage of indirect research costs, Canadian research sovereignty, strengthening capacity and the economic benefits of domestic research, research commercialization. Increasing access to care including models of care, removing barriers to care, particularly for underserved communities, using innovative approaches to improve access to care including AI to improve timely diagnosis and treatment. Issu

Communications regarding funding from various Government funding programs, opportunities to improve government activity (funding, tax incentives, clinical trials infrastructure, etc) to encourage the innovation economy in Canada with a specific focus on biotech, and programs around procurement opportunities for the Government of Canada relating to biotechnology products.

Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada. Communication regarding free trade agreements as they relate to the biopharmaceutical industry. The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Public Health Agency of Canada, regarding the federal response to the hepatitis C virus. Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada. Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages. Communications with Heath Canada regarding modernization of the medical devices regulatory framework. Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products. Communications with Health Canada regarding the application of its nitrosamine guidelines. Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials. Communications with Health Canada regarding guidelines for pediatric action plans. Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy. Communications regarding national pharmacare legislation, regulations, policies or programs. Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime. Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices. Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.

Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada Annual federal Budgets and Budget updates relating to the biopharmaceutical industry. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.

Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

Create and fund a Vision Health Desk and Chief Vision Officer at Health Canada or the Public Health Agency of Canada. Develop and implement a National Strategy for Vision Health

Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases. Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board as they relate to access for patients to rare disease medicines Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries. Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines. Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Scientific Research and Experimental Development Tax Incentive Program as it pertains to research and development of treatments for rare disorders. Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders. Implementation of the Pharmacare Act as it relates to rare disease medicines. Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Protect children and youth from online harms by advancing evidence-informed policies (Bill C-34) that promote safer digital environments, support healthy development and well-being, and strengthen protections against harmful online content, interactions, and platform practices. PT stream of the Build Communities Strong Fund, specifically the $5 billion announced specifically for healthcare infrastructure, making sure that children's healthcare needs are taken into account in the program development. Creation of an Indigenous Guiding Circle within Children's Healthcare Canada to provide guidance and counsel on how to better advocate for FNIM children and youth health issues. Protect the Public Health Agency of Canada’s critical work, building confidence in vaccines for children and combatting mis and disinformation influencing decisions impacting children’s health. Protect and expand capacity to deliver on Jordan’s Principle and the Inuit Child First Initiative (a federal responsibility); Top up and broaden the eligibility for the Youth Mental Health Fund, with a focus on prevention, early assessment and rapid intervention in the early years; Include Children’s Priorities in Nation-Building Investments : Asking for capital investments in the children’s healthcare system, including support for research, workforce planning, and the implementation of learning health systems. Advancing a National Children's Strategy to advance child and youth health and well-being outcomes.